South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India's global biotech company Biocon Ltd. for an obesity treatment containing liraglutide.
This treatment is a glucagon-like peptide-1 (GLP-1) analog based on synthetic peptide technology.
Liraglutide is the main ingredient in Saxenda, an obesity treatment by the Danish biotech company Novo Nordisk.
"Through collaboration with Biocon, we can expand our portfolio into the obesity sector. We will leverage our competitive edge as a leader in the diabetes business to successfully launch and grow this product," Chairman of Handok Kim YoungJin said.
Write to Jeong Min Nam at
peux@hankyung.com
